A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces

Journal of Biomedical Materials Research

Volumn 37, Issue 4, 1997, Pages 474-480

  Gemmell, Cynthia H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Biomaterials; C3d; C5b 9; Complement; IC3b; Protein adsorption

Indexed keywords

FLOW CYTOMETRIC IMMUNOASSAY;

ADSORPTION; BIOMATERIALS; CROSSLINKING; FLUORESCENCE; IMMUNOLOGY; MONOCLONAL ANTIBODIES; POLYSTYRENES; PROTEINS;

BIOASSAY;

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADSORPTION; ARTICLE; COMPLEMENT ACTIVATION; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; PROTEIN DETERMINATION;

ADSORPTION; ANIMALS; ANTIBODIES, MONOCLONAL; BIOCOMPATIBLE MATERIALS; CATTLE; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C3D; COMPLEMENT SYSTEM PROTEINS; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOASSAY; KINETICS; MATERIALS TESTING; MICE; MICROSPHERES; POLYSTYRENES; SEPHAROSE; SURFACE PROPERTIES;

EID: 9844246440     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4636(19971215)37:4<474::AID-JBM5>3.0.CO;2-I     Document Type: Article

References (21)

1. R. M. Hakim, "Complement activation by biomaterials," Cardiovasc. Pathol., 2, 187S-197S (1993).
2. J. Janatova, A. K. Cheung, and C. J. Parker, "Biomedical polymers differ in their capacity to activate complement," Complement. Inflamm., 8, 61-69 (1991).
3. P. R. Craddock, J. Fehr, A. P. Dalmasso, K. L. Brigham, and H. S. Jacobs, "Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membrane," J. Clin. Invest., 59, 879-888 (1977).
4. A. C. Hauser, K. Derfler, F. Stockenhuber, O. Janata, and P. Balcke, "Generation of the Membrane Attack Complex during haemodialysis: impact of classical and alternative pathway components," Clinical Science, 79, 471-176 (1990).
5. K. Kottke-Marchant, J. M. Anderson, K. M. Miller, R. E. Marchant, and H. Lazarus, "Vascular graft-associated complement activation and leukocyte adhesion in an artificial circulation," J. Biomed Mater. Res., 21, 379-397 (1987).
6. G. A. Herzlinger and R. D. Cumming, "Role of complement activation in cell adhesion to polymer blood contact surfaces," Trans. ASAIO, 26, 165-171 (1980).
7. C. S. Rinder, H. M. Rinder, B. R. Smith, J. C. Fitch, M. J. Smith, J. B. Tracey, L. A. Matis, S. P. Squinto, and S. A. Rollins, "Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation," J. Clin. Inv., 96, 1564-1572 (1995).
8. C. H. Gemmell, J. P. Black, E. L. Yeo, and M. V. Sefton, "Material induced up-regulation of leukocyte CD11b during whole blood contact: Material differences and a role for complement," J. Biomed. Mater. Res., 32, 29-35 (1996).
9. A. K. McNally and J. M. Anderson, "Complement C3 participation in monocyte adhesion to different surfaces," PNAS USA, 91, 10119-10123 (1994).
10. A. M. Gillinov, J. M. Redmond, J. A. Winkelstein, K. J. Zehr, A. Herskowitz, W. A. Baumgartner, and D. E. Cameron, "Complement and neutrophil activation during cardiopulmonary bypass: A study in the complement-deficient dog," Ann. Thorac. Surg., 57, 345-352 (1994).
11. R. Deppisch, V. Schmitt, J. Bommer, G. M. Hansch, E. Ritz, and E. W. Rauterberg, "Fluid phase generation of terminal complement complex as a novel index of bioincompatibility," Kidney Int., 37, 696-706 (1990).
12. M. Berger, B. Broxup, and M. V. Sefton, "Using Elisa to evaluate complement activation by reference biomaterials," J. Mater. Sci. Mater. Med., 5, 622-627 (1994).
13. A. Kandus, R. Ponikvar, J. Drinovec, S. Kladnik, and P. Ivanovich, "Anaphylatoxins C3a and C5a adsorption on acrylonitrile membrane of hollow-fiber and plate dialyzer - an in vivo study," Int. J. Artif. Organs, 13, 176-180 (1990).
14. H. F. Weisman, T. Bartow, M. K. Leppo, H. C. Marsh, Jr., G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon, "Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis," Science, 249, 146-151 (1990).
15. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds., Current Protocols in Immunology, Vol. 2, Wiley, New York, 1994, Chapter 13.
16. R. B. Sim., T. M. Twose, D. S. Paterson, and E. Sim, "The covalent-binding reaction of complement component C3," Biochem. J., 193, 115-127 (1981).
17. M. D. Kazatchkine and U. E. Nydegger, "The human alternative complement pathway: Biology and immunopathology of activation and regulation," Prog. Allergy, 30, 193-234 (1982).
18. S. R. Mulzer and J. L. Brash, "Identification of plasma proteins adsorbed to hemodialyzers during clinical use," J. Biomed. Mater. Res., 23, 1483-1504 (1989).
19. M. P. Carreno, D. Labarre, F. Maillet, M. Jozefowicz, and M. D. Kazatchkine, "Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface bound C3b and chemical groups on nonactivating surfaces," Eur. J. Immunol., 19, 2145-2150 (1989).
20. J. Toufib and D. Labarre, "Relationship between reduction of complement activation by polysaccharide surfaces bearing diethylaminoethyl groups and their degree of substitution," Biomaterials, 16, 1081-1088 (1995).
21. J. P. Black, E. L. Yeo, and M. V. Sefton, "An enzyme-linked immunoflow assay for quantifying complement activation," in Fifth World Biomaterials Congress, Volume 1, May 29-June 2, Toronto, Canada, 1996, p. 332.